Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma
Authors:
- Juan Carlos Gallardo-PérezJGJuan Carlos Gallardo-Pérez
- María Cristina Trejo-SolísMTMaría Cristina Trejo-Solís
- Diana Xochiquetzal Robledo-CadenaDRDiana Xochiquetzal Robledo-Cadena
- Rebeca López-MarureRLRebeca López-Marure
- Lourdes Teresa Agredano-MorenoLALourdes Teresa Agredano-Moreno
- Luis Felipe Jimenez-GarcíaLJLuis Felipe Jimenez-García
- Laura Gabriela Sánchez-LozadaLSLaura Gabriela Sánchez-Lozada
- 23 February 2023
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 40 (3) , 1-14
Abstract
Glioblastoma (GBM) is the most frequent brain cancer and more lethal than other cancers. Characteristics of this cancer are its high drug resistance, high recurrence rate and invasiveness. Invasiveness in GBM is related to overexpression of matrix metalloproteinases (MMPs) which are mediated by wnt/β-catenin and induced by the activation of signaling pathways extracellularly activated by the cytokine neuroleukin (NLK) in cancer stem cells (CSC). Therefore, in this work we evaluated the effect of the tetrose saccharide, erythrose (Ery), a NLK inhibitor of invasiveness and drug sensitization in glioblastoma stem cells (GSC). GSC were obtained from parental U373 cell line by a CSC phenotype enrichment protocol based on microenvironmental stress conditions such as hypoxia, hipoglycemia, drug exposition and serum starvation. Enriched fraction of GSC overexpressed the typical markers of brain CSC: low CD133+ and high CD44; in addition, epithelial to mesenchyme transition (EMT) markers and MMPs were increased several times in GSC vs. U373 correlating with higher invasiveness, elongated and tubular mitochondrion and temozolomide (TMZ) resistance. IC50 of Ery was found at nM concentration and at 24 h induced a severe diminution of EMT markers, MMPs and invasiveness in GSC. Furthermore, the phosphorylation pattern of NLK after Ery exposition also was affected. In addition, when Ery was administered to GSC at subIC50, it was capable of reverting TMZ resistance at concentrations innocuous to non-tumor cancer cells. Moreover, Ery added daily induced the death of all GSC. Those findings indicated that the phytodrug Ery could be used as adjuvant therapy in GBM.Keywords
This publication has 45 references indexed in Scilit:
- GPI/AMF inhibition blocks the development of the metastatic phenotype of mature multi-cellular tumor spheroidsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014
- Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherinPLOS ONE, 2013
- Mitochondrial dynamics regulates migration and invasion of breast cancer cellsOncogene, 2012
- A complete compilation of matrix metalloproteinase expression in human malignant gliomasWorld Journal of Clinical Oncology, 2012
- Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activityInternational Journal of Oncology, 2010
- Phosphoglucose Isomerase/Autocrine Motility Factor Mediates Epithelial and Mesenchymal Phenotype Conversions in Breast CancerCancer Research, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxiaThe FASEB Journal, 2005
- Visualizing Nuclear Structure In Situ by Atomic Force Microscopy2004
- Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf‐1 and Caspase‐9 apoptosome expressionInternational Journal of Cancer, 2003